ASCIL Biopharm
Av. Universitat Autònoma, 1B, Cerdanyola del Vallès, Catalonia, 08290, Spain
Overview
ASCIL Biopharm is a drug-delivery company developing proprietary miniaturized injectable and locally acting therapeutics to enhance the safety, effectiveness, and convenience of administration of drugs for chronic high burden diseases. The company's mission is to create pharmaceutical products and therapeutic treatments of improved efficacy, comfort, and compliance through its new patented DDS technology platforms.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Health Care
Investment portfolio
- Iproteos
Participated · Equity · Oct 2016
Iproteos is a biotech spin-off based at the Parc Cientific de Barcelona that is advancing a first-in-class drug for Cognitive Impairment Associated with Schizophrenia (CIAS) using its proprietary IPROTech platform. The company was created in 2011 by Teresa Tarragó and Ernest Giralt following technology transfer from IRB Barcelona and the University of Barcelona Biotech. Iproteos focuses on therapeutic peptides as the basis for its lead compound. The firm plans to complete regulatory preclinical phases and then carry out human clinical trials, starting with Phase I. The recently closed funding will be used to finish preclinical work and enable the start of human Phase I trials. No operating metrics were reported in the article.
Team
No current team members are available.